Crinetics Pharmaceuticals Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings data on Thursday, May, 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.03.
View Crinetics Pharmaceuticals' earnings history.

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRNX shares have increased by 22.2% and is now trading at $18.94.
View which stocks have been most impacted by COVID-19.

5 analysts have issued 12 month price targets for Crinetics Pharmaceuticals' stock. Their forecasts range from $33.00 to $42.00. On average, they anticipate Crinetics Pharmaceuticals' stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 105.9% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals or view top-rated stocks among Wall Street analysts.

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Crinetics Pharmaceuticals include Cryoport (CYRX), MorphoSys (MOR), Pacira BioSciences (PCRX), Prestige Consumer Healthcare (PBH), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), Global Blood Therapeutics (GBT), OPKO Health (OPK), ALX Oncology (ALXO), FibroGen (FGEN), Morphic (MORF), Zentalis Pharmaceuticals (ZNTL), Nuvation Bio (NUVB), Xencor (XNCR) and Centessa Pharmaceuticals (CNTA).
View all of CRNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (5.89%), BlackRock Inc. (5.76%), Point72 Asset Management L.P. (3.39%), Geode Capital Management LLC (1.00%), Northern Trust Corp (0.79%) and Bank of New York Mellon Corp (0.76%). Company insiders that own Crinetics Pharmaceuticals stock include Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Ventures Iv LP 5Am and Vivo Capital Viii, Llc.
View institutional ownership trends for Crinetics Pharmaceuticals.

CRNX stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Price T Rowe Associates Inc. MD, Northern Trust Corp, PDT Partners LLC, JPMorgan Chase & Co., Credit Suisse AG, Nuveen Asset Management LLC, and Citigroup Inc..
View insider buying and selling activity for Crinetics Pharmaceuticals or view top insider-selling stocks.

CRNX stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Opaleye Management Inc., Geode Capital Management LLC, BlackRock Inc., Point72 Asset Management L.P., Dimensional Fund Advisors LP, Victory Capital Management Inc., and Morgan Stanley. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Perceptive Advisors Llc, and Richard Scott Struthers.
View insider buying and selling activity for Crinetics Pharmaceuticals or or view top insider-buying stocks.

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRNX stock can currently be purchased for approximately $18.94.

Crinetics Pharmaceuticals has a market capitalization of $712.01 million and generates $70,000.00 in revenue each year. The company earns $-73,810,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

Crinetics Pharmaceuticals employs 93 workers across the globe.

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]